Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2013
[Clinical analysis of 20 patients with primary non-Hodgkin's lymphoma of nasal cavity and nasopharynx].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Abulajiang, Youledusi, Gu Xingzhi
Аннотация
OBJECTIVE: To evaluate the treatment policy for non-Hodgkin's lymphoma of the nasal cavity and nasopharynx.
METHOD: Twenty patients with pathologically confirmed non-Hodgkin's lymphoma of nasal cavity and nasopharynx,treated from Jan. 2006 to Oct. 2010, were retrospectively reviewed.
RESULT: The 3-year overall survival and complete response rates for all patients were 78% and 47% respectively. The 3-year overall survival rates for patients treated with chemotherapy and patients treated with chemotherapy plus radiotherapy were 75% and 82% respectively. The estimates of complete response for patients receiving chemotherapy alone and for patients receiving chemotherapy plus radiotherapy were 37% and 55%, respectively. The 3-year overall survival rates for patients who achieved complete response and patients who did not were 89% and 70%, respectively. The 3-year overall survival rates for patients in stage IE and stage II E were 92% and 57%, respectively.
CONCLUSION: There was no significant difference between chemotherapy alone and chemotherapy plus radiotherapy for the treatment of non-Hodgkin's lymphoma of the nasal cavity and nasopharynx. The 3-year overall survival rate for patients in stage IE was much higher than in stage II E. Early treatment is very important to improve the survival rate of the patients.
METHOD: Twenty patients with pathologically confirmed non-Hodgkin's lymphoma of nasal cavity and nasopharynx,treated from Jan. 2006 to Oct. 2010, were retrospectively reviewed.
RESULT: The 3-year overall survival and complete response rates for all patients were 78% and 47% respectively. The 3-year overall survival rates for patients treated with chemotherapy and patients treated with chemotherapy plus radiotherapy were 75% and 82% respectively. The estimates of complete response for patients receiving chemotherapy alone and for patients receiving chemotherapy plus radiotherapy were 37% and 55%, respectively. The 3-year overall survival rates for patients who achieved complete response and patients who did not were 89% and 70%, respectively. The 3-year overall survival rates for patients in stage IE and stage II E were 92% and 57%, respectively.
CONCLUSION: There was no significant difference between chemotherapy alone and chemotherapy plus radiotherapy for the treatment of non-Hodgkin's lymphoma of the nasal cavity and nasopharynx. The 3-year overall survival rate for patients in stage IE was much higher than in stage II E. Early treatment is very important to improve the survival rate of the patients.